ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Ibuprofen

Also written as “ibuprofen”, “Intravenous ibuprofen” and “Ibuprofen/acetaminophen”.

Its studies are mostly in Pain · Pain, Postoperative · Osteoarthritis · Fever · Osteoarthritis, Knee, led by 36 companies.

Drug pageIbuprofen: every studyMany companies study it; this page follows only the 101 they lead. All 433 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 22, 2008101 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only150 open or runningphase 4since Aug 22, 2008Aug 22, 2008none ahead
Cumberland Pharmaceuticalsits history only90 open or runningphase 4since Apr 12, 2011Sep 22, 2005none ahead
Johnson & Johnsonits history only70 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Boehringer Ingelheimits history only60 open or runningphase 3since Aug 22, 2013Jul 26, 2010none ahead
Dr. Reddy's Laboratoriesits history only60 open or runningphase 1since Jan 20, 2010Jan 20, 2010none ahead
Reckittits history only60 open or runningphase 3since Oct 26, 2010Oct 26, 2010none ahead
AFT Pharmaceuticalsits history only51 open or runningphase 3since Aug 16, 2011Apr 14, 2010Mar 2027phase 3 · NCT07225634
Strategic Science & Technologiesits history only40 open or runningphase 3since Oct 11, 2012Oct 11, 2012none ahead
Angelini Pharmaits history only30 open or runningphase 1since Jun 17, 2015Jun 17, 2015none ahead
GlaxoSmithKlineits history only30 open or runningphase 4since Mar 28, 2013Sep 5, 2006none ahead
SCOLR Pharma10 open or runningphase 3since Jun 26, 2008Jun 26, 2008none ahead

Also a collaborator on its studies: Premier Research Group, Parexel, Aptuit, Cross Research, Pharma Consulting Group AB, Pivotal S.L. and AAIPharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of SCOLR Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2008First study: phase 3 study in PainFirst studyNCT00707057 · 256 enrolled · United States

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The one study SCOLR Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00707057Pain · United States3CompletedOct 2008256

How it is read

Names in the registry

  • “Ibuprofen”, 40 entries
  • “ibuprofen”, 10 entries
  • “Intravenous ibuprofen”, 5 entries
  • “Ibuprofen/acetaminophen”, 4 entries
  • “ibuprofen + caffeine”, 3 entries

Codes read as this program: SST0225.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.